Navigation Links
Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair

HARBIN, China, July 1 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company successfully exhibited its Siberian Ginseng (Acanthopanax)-based products at the 21st China Harbin International Economic and Trade Fair ("Harbin Trade Fair") from June 15 to June 19, 2010.

The Harbin Trade Fair is one of the large-scale foreign trade fairs authorized by the Chinese government. Over the years, Harbin Trade Fair has developed from a regional fair to a large-scale international economic and trade fair with 3,000 international standard booths and 10 professional exhibition areas. Harbin Trade Fair has become one of the most significant international trade fairs in the world -- a window for China to fully explore the diversified international market and a major platform for regional cooperation in Northeast Asia. Renhuang's booth showcased the Company's wide range of Siberian Ginseng-based medications and was visited by thousands of interested attendees. Siberian Ginseng has well-documented health benefits for treating depression and anxiety without the side effects often associated with chemical-based drugs.

The Company signed ten new letters of intent with distributors at the Harbin Trade Fair, which the Company estimates will contribute approximately RMB3.0 million (approximately $0.4 million) to its fiscal year 2010 revenue.

"Our participation at the Harbin Trade Fair was of great significance for enhancing our corporate image and increasing our brand influence," said Mr. Shaoming Li, Chairman and Chief Executive Officer of Renhuang. "Harbin Trade Fair provides a key trade discussion platform for domestic and international enterprises. We are delighted that our Siberian Ginseng-based products command positive market recognition and growing acceptance in the industry, and we look forward to participating in similar trade shows to enhance our visibility and build industry and customer relationships."


Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: .

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's participation in the 21st China Harbin International Economic and Trade Fair and expected positive outcomes, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    For more information, please contact:

    Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Phone: +86-451-8260-2162

    CCG Investor Relations:
     Mr. Mark Collinson, Partner
     Phone: +1-310-954-1343 (Los Angeles)

     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)

SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang to Launch New Bio-pharmaceutical Product - Ginseng and Deer Antler Extract
2. Renhuang to Launch New All-Natural Anti-depressant and Nerve Regulation Product - Compound Schisandra Tablets
3. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
4. Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results
5. Renhuang Appoints PricewaterhouseCoopers to Develop a SOX 404 Compliance Program
6. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
7. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 107th China Import and Export Fair
8. Renhuang Elected as Deputy Chair Unit of Heilongjiang Medical Association
9. Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
10. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
11. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
Post Your Comments:
(Date:10/13/2015)... 13, 2015  Measurement in accountable care programs ... financial incentives, but gaps in measurement can result ... health systems. A new, peer-reviewed study published ... explores measurement gaps for high-priority conditions ... --> --> "These ...
(Date:10/13/2015)... , Oct. 13, 2015  Nanomedical Diagnostics, ... use in research and diagnostics, announces the completion ... million led by Serra Ventures. ... is providing low-cost, easy-to-use monitoring and diagnostic platforms ... decisions. The funding round will enable the company ...
(Date:10/13/2015)... 13 2015 ... the "US & European Markets for ... report to their offering. --> ... of the "US & European Markets ... (2010-2021)" report to their offering. ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ... IBM software products, introduced a new company, RightSensor™ LLC, an Internet of Things ... capability. RightSensor™ provides a fully-managed approach for customers requiring sensor hardware for ...
(Date:10/13/2015)... CHENNAI, India (PRWEB) , ... October 13, 2015 , ... ... advanced camera solutions, today announced See3CAM_CU40, the industry’s first RGB-IR pixel format ... module. See3CAM_CU40, a new member of e-con’s See3CAM family of UVC USB 3.0 cameras, ...
(Date:10/13/2015)... ... October 13, 2015 , ... Protein is essential to good health. You need ... blood. But how much protein does the average man need in order to stay ... the October 2015 issue of Harvard Men's Health Watch . Most Americans get ...
(Date:10/13/2015)... ... 2015 , ... T-System and Centegra Health System, a prominent ... visits per year, today announced the successful and rapid deployment of EV™, an ... financial outcomes. , In less than four days, Centegra Hospitals McHenry ...
(Date:10/13/2015)... ... October 13, 2015 , ... World Patent Marketing , a ... snow melting invention that helps people in clearing snow away from the streets and ... grow at 3.8% per year," says Scott Cooper, CEO and Creative Director of World ...
Breaking Medicine News(10 mins):